EP1202750A4 - Traitement de l'infection par vih et de ses infections opportunistes - Google Patents

Traitement de l'infection par vih et de ses infections opportunistes

Info

Publication number
EP1202750A4
EP1202750A4 EP98918740A EP98918740A EP1202750A4 EP 1202750 A4 EP1202750 A4 EP 1202750A4 EP 98918740 A EP98918740 A EP 98918740A EP 98918740 A EP98918740 A EP 98918740A EP 1202750 A4 EP1202750 A4 EP 1202750A4
Authority
EP
European Patent Office
Prior art keywords
hiv infection
treating hiv
secondary infections
related secondary
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98918740A
Other languages
German (de)
English (en)
Other versions
EP1202750A1 (fr
Inventor
Arsinur Burcoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1202750A1 publication Critical patent/EP1202750A1/fr
Publication of EP1202750A4 publication Critical patent/EP1202750A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98918740A 1997-04-28 1998-04-28 Traitement de l'infection par vih et de ses infections opportunistes Withdrawn EP1202750A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84801397A 1997-04-28 1997-04-28
US848013 1997-04-28
PCT/US1998/008357 WO1998048843A1 (fr) 1997-04-28 1998-04-28 Traitement de l'infection par vih et de ses infections opportunistes

Publications (2)

Publication Number Publication Date
EP1202750A1 EP1202750A1 (fr) 2002-05-08
EP1202750A4 true EP1202750A4 (fr) 2002-10-16

Family

ID=25302109

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98918740A Withdrawn EP1202750A4 (fr) 1997-04-28 1998-04-28 Traitement de l'infection par vih et de ses infections opportunistes

Country Status (5)

Country Link
EP (1) EP1202750A4 (fr)
AU (1) AU754242B2 (fr)
CA (1) CA2259041A1 (fr)
HK (1) HK1044896A1 (fr)
WO (1) WO1998048843A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039304A2 (fr) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
AU2003238189A1 (en) * 2002-05-31 2003-12-19 Klinikum Der Universitat Regensburg Method for the protection of endothelial and epithelial cells during chemotherapy
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
AU2005216971A1 (en) * 2004-02-25 2005-09-09 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Office Of Technology Transfer Methylation inhibitor compounds
JP5714203B2 (ja) * 2005-03-03 2015-05-07 ゲンチウム エスピーエー 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド
AU2007231651B2 (en) * 2005-03-03 2011-09-15 Gentium Spa Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
ITMI20050336A1 (it) * 2005-03-03 2006-09-04 Gentium Spa Formulazione ad attivita' anti-tumorale
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
DK2864496T4 (da) 2012-06-22 2021-01-04 Gentium S R L Euglobulin-baseret fremgangsmåde til bestemmelse af den biologiske aktivitet af defibrotid
EP3026122A1 (fr) 2014-11-27 2016-06-01 Gentium S.p.A. Procédé à base cellulaire pour déterminer la puissance de défibrotide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017246A1 (fr) * 1990-05-04 1991-11-14 Isis Pharmaceuticals, Inc. Procedes de modulation de l'expression des genes par l'interference dans la structure secondaire de l'arn
EP0558833A2 (fr) * 1991-12-09 1993-09-08 Crinos Industria Farmacobiologica S.p.A. Oligodéoxyribonucléotides avec un activité anti-ischemic et leur procédés de préparation
WO1994015621A1 (fr) * 1993-01-13 1994-07-21 Arsinur Burcoglu Procede d'utilisation de polynucleotides, d'oligonucleotides et de leurs derives pour traiter divers etats pathologiques
WO1995004068A1 (fr) * 1993-07-29 1995-02-09 Isis Pharmaceuticals, Inc. Oligomeres permettant de moduler le virus de l'immunodeficience humaine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170215B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017246A1 (fr) * 1990-05-04 1991-11-14 Isis Pharmaceuticals, Inc. Procedes de modulation de l'expression des genes par l'interference dans la structure secondaire de l'arn
EP0558833A2 (fr) * 1991-12-09 1993-09-08 Crinos Industria Farmacobiologica S.p.A. Oligodéoxyribonucléotides avec un activité anti-ischemic et leur procédés de préparation
WO1994015621A1 (fr) * 1993-01-13 1994-07-21 Arsinur Burcoglu Procede d'utilisation de polynucleotides, d'oligonucleotides et de leurs derives pour traiter divers etats pathologiques
WO1995004068A1 (fr) * 1993-07-29 1995-02-09 Isis Pharmaceuticals, Inc. Oligomeres permettant de moduler le virus de l'immunodeficience humaine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRACHT ET AL: "Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 200, no. 2, 29 April 1994 (1994-04-29), pages 933 - 937, XP002112704, ISSN: 0006-291X *
HIZAL NURPERI ET AL: "Investigation of the fibrinolytic activity of defibrotide fractions.", GENERAL PHARMACOLOGY, vol. 25, no. 8, 1994, pages 1617 - 1620, XP008007140, ISSN: 0306-3623 *
See also references of WO9848843A1 *

Also Published As

Publication number Publication date
CA2259041A1 (fr) 1998-11-05
AU7160998A (en) 1998-11-24
WO1998048843A1 (fr) 1998-11-05
HK1044896A1 (zh) 2002-11-08
EP1202750A1 (fr) 2002-05-08
AU754242B2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
IL129352A0 (en) Benzimidazole-2- carbamates for the treatment of viral infections and cancer
EP0831873A4 (fr) Therapie combinatoire pour le traitement d'infections virales vih et autres
IL139002A0 (en) Compositions for the treatment of hiv and other viral infections
HK1023371A1 (en) Compositions and methods for treating viral infections
PL335160A1 (en) Treatment of hiv and carcinoma
AU8452698A (en) Industrial fabrics and method of treatment
EP0569703A3 (fr) Méthode de traitement et prévention d'infections virales utilisant HBNF et protéine MK.
EP1202750A4 (fr) Traitement de l'infection par vih et de ses infections opportunistes
PL312908A1 (en) Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors
GB9304746D0 (en) Treatment of viral infections
EP0726775A4 (fr) Vaccin et procede de traitement contre les infections a chlamydia
EP0921803A4 (fr) Procede permettant de prevenir et de traiter une infection pestivirale et les maladies qui y sont associees
ZA9510108B (en) Composition and method for prevention and treatment of HIV-1 infection
AU4602897A (en) Method for treatment of immunodeficiency virus infection
IL116925A (en) Combinations of compounds useful for treating HIV infections and pharmaceutical compositions comprising these combinations
ZA972722B (en) Method for prevention and treatment of viral infectious diseases.
EP0789565A4 (fr) Prevention de l'infection par le vih
AU2473695A (en) Method of slowing the progression of hiv infection
PL317876A1 (en) Combined treatment of hiv infections
AU3530395A (en) Treatment of viral infections
AU3553195A (en) Methods of identifying agents which block hiv infection
AU6605196A (en) Method of treating hepatitis delta virus infection
AU5085693A (en) Method of treating epstein-barr virus infection
AU6559194A (en) Method of treating hepatitis b infection
AU2001288870A1 (en) Antiviral compounds and method of treating viral infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020903

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20040909

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060916

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044896

Country of ref document: HK